VWF antibody detection and inhibitor characterization within type 3 VWD cohort (N = 49)
| VWF Abs in Zimmerman type 3 VWD index cases . | No. of patients/total patients (%) . |
|---|---|
| VWF antibody positive | 9/49 (18%) |
| IgG positive | 8/9 (89%) |
| IgM positive | 1/9 (11%) |
| Nonneutralizing antibodies | 3/9 (33%) |
| Neutralizing/inhibitory antibodies | 6/9 (67%) |
| VWF:F8 inhibitor | 5/9 (56%) |
| VWF:CB3 inhibitor | 3/9 (33%) |
| VWF:GPIbM inhibitor | 2/9 (22%) |
| VWF:CB4 inhibitor | 1/9 (11%) |
| VWF Abs in Zimmerman type 3 VWD index cases . | No. of patients/total patients (%) . |
|---|---|
| VWF antibody positive | 9/49 (18%) |
| IgG positive | 8/9 (89%) |
| IgM positive | 1/9 (11%) |
| Nonneutralizing antibodies | 3/9 (33%) |
| Neutralizing/inhibitory antibodies | 6/9 (67%) |
| VWF:F8 inhibitor | 5/9 (56%) |
| VWF:CB3 inhibitor | 3/9 (33%) |
| VWF:GPIbM inhibitor | 2/9 (22%) |
| VWF:CB4 inhibitor | 1/9 (11%) |